Stryker (NYSE:SYK) Issues Earnings Results

Stryker (NYSE:SYK) posted its quarterly earnings data on Tuesday. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14, Zacks reports. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker updated its FY 2025 guidance to 13.450-13.700 EPS.

Stryker Price Performance

Shares of NYSE SYK traded down $4.98 on Tuesday, hitting $394.92. The company’s stock had a trading volume of 1,991,191 shares, compared to its average volume of 1,494,289. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The stock has a 50 day moving average of $376.32 and a 200-day moving average of $361.59. Stryker has a 12-month low of $310.74 and a 12-month high of $406.19. The company has a market capitalization of $150.55 billion, a price-to-earnings ratio of 42.33, a price-to-earnings-growth ratio of 2.68 and a beta of 0.95.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend is Tuesday, December 31st. Stryker’s dividend payout ratio (DPR) is 36.01%.

Analyst Upgrades and Downgrades

SYK has been the topic of several research reports. Citigroup raised their price objective on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $425.00 price objective on shares of Stryker in a research report on Tuesday, January 7th. Barclays boosted their target price on Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Finally, Truist Financial increased their price target on Stryker from $380.00 to $409.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $405.80.

Insider Buying and Selling

In other news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.